...
首页> 外文期刊>Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis >Heterozygous carrier of G20210A prothrombin mutation used oral contraceptive treatment for 23 years without thrombotic events, and developed cerebral venous thrombosis 1 month after resumption of the medication at the age of 50.
【24h】

Heterozygous carrier of G20210A prothrombin mutation used oral contraceptive treatment for 23 years without thrombotic events, and developed cerebral venous thrombosis 1 month after resumption of the medication at the age of 50.

机译:G20210A凝血酶原突变的杂合子携带者在口服避孕药的情况下治疗了23年,未发生血栓形成事件,并在50岁时恢复用药后1个月出现脑静脉血栓形成。

获取原文
获取原文并翻译 | 示例

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号